139 related articles for article (PubMed ID: 11984146)
1. Pharmacokinetic study of esomeprazole in patients with hepatic impairment.
Sjövall H; Björnsson E; Holmberg J; Hasselgren G; Röhss K; Hassan-Alin M
Eur J Gastroenterol Hepatol; 2002 May; 14(5):491-6. PubMed ID: 11984146
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic study of esomeprazole in the elderly.
Hasselgren G; Hassan-Alin M; Andersson T; Claar-Nilsson C; Röhss K
Clin Pharmacokinet; 2001; 40(2):145-50. PubMed ID: 11286324
[TBL] [Abstract][Full Text] [Related]
3. Intra-oesophageal pH profiles and pharmacokinetics of pantoprazole and esomeprazole: a crossover study in patients with gastro-oesophageal reflux disease.
Simon B; Müller P; Pascu O; Gatz G; Sander P; Huber R; Mascher H
Eur J Gastroenterol Hepatol; 2003 Jul; 15(7):791-9. PubMed ID: 12811310
[TBL] [Abstract][Full Text] [Related]
4. A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects.
Hassan-Alin M; Andersson T; Niazi M; Röhss K
Eur J Clin Pharmacol; 2005 Jan; 60(11):779-84. PubMed ID: 15578172
[TBL] [Abstract][Full Text] [Related]
5. Intravenous esomeprazole (40 mg and 20 mg) inhibits gastric acid secretion as effectively as oral esomeprazole: results of two randomized clinical studies.
Wilder-Smith CH; Bondarov P; Lundgren M; Niazi M; Röhss K; Ahlbom H; Nyman L
Eur J Gastroenterol Hepatol; 2005 Feb; 17(2):191-7. PubMed ID: 15674097
[TBL] [Abstract][Full Text] [Related]
6. The pharmacokinetics, pharmacodynamics and safety of oral doses of ilaprazole 10, 20 and 40 mg and esomeprazole 40 mg in healthy subjects: a randomised, open-label crossover study.
Shin JS; Lee JY; Cho KH; Park HL; Kukulka M; Wu JT; Kim DY; Park SH
Aliment Pharmacol Ther; 2014 Sep; 40(5):548-61. PubMed ID: 25041486
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects.
Hassan-Alin M; Andersson T; Bredberg E; Röhss K
Eur J Clin Pharmacol; 2000 Dec; 56(9-10):665-70. PubMed ID: 11214773
[TBL] [Abstract][Full Text] [Related]
8. Esomeprazole provides improved acid control vs. omeprazole In patients with symptoms of gastro-oesophageal reflux disease.
Lind T; Rydberg L; Kylebäck A; Jonsson A; Andersson T; Hasselgren G; Holmberg J; Röhss K
Aliment Pharmacol Ther; 2000 Jul; 14(7):861-7. PubMed ID: 10886041
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the pharmacokinetic interaction between esomeprazole (40 mg) and acetylsalicylic acid (325 mg) in healthy volunteers.
Niazi M; Andersson T; Nauclér E; Sundin M; Naesdal J
Int J Clin Pharmacol Ther; 2009 Sep; 47(9):564-9. PubMed ID: 19761715
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: A randomized, open-label study.
Li J; Zhao J; Hamer-Maansson JE; Andersson T; Fulmer R; Illueca M; Lundborg P
Clin Ther; 2006 Mar; 28(3):419-27. PubMed ID: 16750456
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and Acid Suppressant Efficacy of Esomeprazole after Intravenous, Oral, and Subcutaneous Administration to Healthy Beagle Dogs.
Hwang JH; Jeong JW; Song GH; Koo TS; Seo KW
J Vet Intern Med; 2017 May; 31(3):743-750. PubMed ID: 28407418
[TBL] [Abstract][Full Text] [Related]
12. Oral esomeprazole in Japanese pediatric patients with gastric acid-related disease: Safety, efficacy, and pharmacokinetics.
Shimizu T; Nakayama Y; Ishii E; Ida S; Satou T; Tokuhara D; Arai K; Nii M; Rydholm H; Yajima T;
Pediatr Int; 2019 Jan; 61(1):87-95. PubMed ID: 30422368
[TBL] [Abstract][Full Text] [Related]
13. Esomeprazole MUPS 40 mg tablets and esomeprazole MUPS 40 mg tablets encapsulated in hard gelatine are bioequivalent.
Talpes S; Knoerzer D; Huber R; Pfaffenberger B
Int J Clin Pharmacol Ther; 2005 Jan; 43(1):51-6. PubMed ID: 15704615
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers.
Choi Y; Han H; Shin D; Lim KS; Yu KS
Drug Des Devel Ther; 2015; 9():4127-35. PubMed ID: 26257511
[TBL] [Abstract][Full Text] [Related]
15. The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pH.
Junghard O; Hassan-Alin M; Hasselgren G
Eur J Clin Pharmacol; 2002 Oct; 58(7):453-8. PubMed ID: 12389067
[TBL] [Abstract][Full Text] [Related]
16. Studies on drug interactions between esomeprazole, amoxicillin and clarithromycin in healthy subjects.
Hassan-Alin M; Andersson T; Niazi M; Liljeblad M; Persson BA; Röhss K
Int J Clin Pharmacol Ther; 2006 Mar; 44(3):119-27. PubMed ID: 16550734
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, pharmacodynamics, and safety of esomeprazole injection/infusion in healthy Chinese volunteers: a five-way crossover study.
Yang H; Li J; Zhao Q; Li J; Shen K; Yang X; Jiang J; Hu P; Qian J
J Gastroenterol Hepatol; 2013 Dec; 28(12):1823-8. PubMed ID: 23800161
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study.
Zhao J; Li J; Hamer-Maansson JE; Andersson T; Fulmer R; Illueca M; Lundborg P
Clin Ther; 2006 Nov; 28(11):1868-76. PubMed ID: 17213007
[TBL] [Abstract][Full Text] [Related]
19. Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data.
Schwab M; Klotz U; Hofmann U; Schaeffeler E; Leodolter A; Malfertheiner P; Treiber G
Clin Pharmacol Ther; 2005 Dec; 78(6):627-34. PubMed ID: 16338278
[TBL] [Abstract][Full Text] [Related]
20. Esomeprazole: a review of its use in the management of acid-related disorders in the US.
Scott LJ; Dunn CJ; Mallarkey G; Sharpe M
Drugs; 2002; 62(7):1091-118. PubMed ID: 11985491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
